Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 9 Nov 2026
Promising but preliminary

Orforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.

In ATTAIN, phase 3, randomized, placebo-controlled trials, orforglipron treatment resulted in substantial weight reduction among people with obesity with or without type 2 diabetes. Across the ATTAIN-1 and ATTAIN-2 trials, orforglipron treatment was associated with substantial body weight reduction and improvements in patient-reported HRQoL, with consistent enhancements in physical functioning and heterogeneous effects on psychosocial functioning.ATTAIN-1: NCT05869903; ATTAIN-2:NCT05872620. © 2026 Published by Elsevier Inc. on behalf of Obesity Medicine Association.

In ATTAIN, phase 3, randomized, placebo-controlled trials, orforglipron treatment resulted in substantial weight reduction among people with obesity with or without type 2 diabetes. Across the ATTAIN-1 and ATTAIN-2 trials, orforglipron treatment was associated with substantial body weight reduction and improvements in patient-reported HRQoL, with consistent enhancements in physical functioning and heterogeneous effects on psychosocial functioning.ATTAIN-1: NCT05869903; ATTAIN-2:NCT05872620. © 2026 Published by Elsevier Inc. on behalf of Obesity Medicine Association.

What the study was

Study design
Randomized controlled trial
Category
Drug Development
Maturity
Potentially Practice-Changing
Journal
Obesity pillars

Why it surfaced

⚪ PROMISING_PRELIMINARY — Promising but preliminary; Watchlist: Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; Design: Randomized controlled trial; species: human

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.